M1 Kliniken AG publishes figures for the 1st quarter of 2021

| Investor News

Successful start to 2021 with significant increase in revenues and earnings in both business segments

  • Group turnover rises to almost EUR 81 million (EUR 23 million in Q1-2020)
  • Group EBITDA amounts to EUR 4.0 million (previous year: EUR 1.4 million); EBIT amounts to EUR 2.6 million (previous year: EUR 0.5 million)
  • Beauty: After restrained treatment figures at the beginning of the quarter, significant increase compared to the previous year at the end of the quarter
  • Trade: Continuation of operational optimisations - sales/result still without effects of COVID antigen rapid tests

Berlin, 1.06.2021 - M1 Kliniken AG (ISIN: DE000A0STSQ8) announces figures for the first quarter of 2021. According to these figures, the consolidated group revenue of the M1 Group in the first quarter of the financial year 2021 rose by approx. 250% year-on-year to just under EUR 81 million (previous year: EUR 23 million). Of this, HAEMATO AG (without M1 Aesthetics), which was not yet consolidated in the same period of the previous year, accounted for sales of a good EUR 59 million.

In the beauty segment, the start into the new year was very restrained due to Corona, with treatment figures that were significantly below the previous year (-20%). Towards the end of the quarter, this picture turned around, so that M1 was able to reach and further increase its historical peak daily sales several times in a row. In Q1-2021 as a whole, just over 81 thousand treatments were performed compared to 73 thousand treatments in the same quarter last year. Turnover in the Beauty segment rose to EUR 13 million after EUR 11.5 million in the previous year. The development in the international locations was particularly pleasing, with treatment numbers increasing from just under 4 thousand (Q1-2020) to over 7 thousand (Q1-2021). Since 12 April 2021, the two locations in the UK have also been reopened, which achieved very pleasing occupancy rates right from the start.

In the trading segment, the ongoing operational optimisation of the business activities of HAEMATO AG is particularly noteworthy, which was able to report a further increase in turnover in the past quarter compared to the previous year. HAEMATO AG was able to significantly improve its profitability. These figures do not yet include the effects of the antigen rapid test approved by the Federal Institute for Drugs and Medical Devices (BfArM) on 23 March 2021 in accordance with Section 11 (1) of the German Medical Devices Act (MPG), the sales of which will significantly positively strengthen the sales and earnings of HAEMATO AG from April.

EBITDA of M1 Kliniken AG in Q1-2021 totalled EUR 4.0 million (previous year: EUR 1.4 million), EBIT amounted to EUR 2.6 million (previous year: EUR 0.5 million). The previous year was marked by the first foothills of the Corona pandemic with the closure of all sites from 23 March 2020. In addition, development and start-up losses of the international sites still burdened the earnings statement in the previous year with a negative EBIT contribution of around EUR 1.0 million, which was limited to a negative EBIT of around EUR 0.2 million in Q1-2021.

"We are convinced that we will be able to successfully continue the course M1 Kliniken AG has embarked upon also in the further course of financial year 2021. By the end of May 2021 four new specialist centres had already been opened in the German market, and at least two more specialist centres are to follow by the end of the year. The search for new locations has also been resumed in the foreign markets, so that the planned number of 50 locations by the end of 2021 is within reach," says the CEO of M1 Kliniken AG, Dr. Walter von Horstig.

Due to the currently ongoing Corona pandemic, M1 Kliniken AG will again make use of the option to invite shareholders to the Company's Annual General Meeting scheduled for 14 July 2021 with an abbreviated notice period of 21 days.

Go back